Replimune Group Inc
NASDAQ:REPL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Crest Nicholson Holdings PLC
LSE:CRST
|
UK |
|
Daol Investment & Securities Co Ltd
KRX:030210
|
KR |
|
A
|
AJAX Engineering Ltd
NSE:AJAXENGG
|
IN |
|
Sasken Technologies Ltd
NSE:SASKEN
|
IN |
|
S
|
Sree Rayalaseema Hi-Strength Hypo Ltd
NSE:SRHHYPOLTD
|
IN |
|
K
|
KSG Agro SA
WSE:KSG
|
UA |
Replimune Group Inc
Operating Expenses
Replimune Group Inc
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Replimune Group Inc
NASDAQ:REPL
|
Operating Expenses
-$325.9m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Expenses
-$22.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Expenses
-$11.4B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Expenses
-$14.1B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Expenses
-$5.7B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Expenses
-$8.5B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-13%
|
|
Replimune Group Inc
Glance View
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. The company is headquartered in Woburn, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2018-07-20. The firm is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The firm applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The firm is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP1 (vusolimogene oderparepvec), RP2, and RP3. The firm is focused on Phase 2 clinical trials with its lead product candidate, RP1, in approximately 240 patients with a range of solid tumors.
See Also
What is Replimune Group Inc's Operating Expenses?
Operating Expenses
-325.9m
USD
Based on the financial report for Dec 31, 2025, Replimune Group Inc's Operating Expenses amounts to -325.9m USD.
What is Replimune Group Inc's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-34%
Over the last year, the Operating Expenses growth was -35%. The average annual Operating Expenses growth rates for Replimune Group Inc have been -28% over the past three years , -34% over the past five years .
